Financial Performance - The company achieved revenue of RMB 277.9 million in 2024, representing a year-on-year increase of 19.6% from RMB 232.3 million in 2023[9]. - Gross profit for the year was RMB 181.7 million, with a gross margin decline attributed to bulk procurement pricing and market competition[9]. - The pre-tax loss significantly narrowed to RMB 12.0 million, a decrease of 88.3% compared to RMB 102.9 million in the previous year[9]. - Revenue increased by 19.6% from RMB 232.3 million for the year ended December 31, 2023, to RMB 277.9 million for the year ended December 31, 2024, primarily due to the growth in sales of acute ischemic stroke treatment devices and hemorrhagic stroke treatment devices[33]. - Gross profit rose from RMB 163.8 million to RMB 181.7 million, while gross margin decreased from 70.5% to 65.4%, mainly due to price impacts from volume-based procurement and market competition[35]. Product Development and Innovation - The company plans to launch at least two major therapeutic devices in the next two years, including a carotid stent and a self-expanding drug stent[9]. - The company introduced two innovative techniques, CATCH and CATCH mini, for treating acute ischemic stroke, improving patient outcomes[10]. - The company has obtained 31 NMPA product registrations, with applications in over 2,500 hospitals domestically[9]. - The company has obtained CE or FDA certifications for several products and is registering over 40 products in 10 countries to expand sales channels[10]. - The company has established a distribution network covering over 2,500 hospitals across all provinces in China, excluding Hong Kong and Macau, supporting its market presence[29]. - The company has developed a comprehensive product pipeline in the neurointervention field, including solutions for acute ischemic stroke and hemorrhagic stroke treatment[178]. - The company aims to continuously launch innovative medical devices to redefine care standards and improve patient outcomes[178]. Research and Development - Research and development costs amounted to RMB 58.9 million to support a diversified pipeline of neurointerventional devices[15]. - R&D costs decreased significantly from RMB 123.8 million to RMB 58.9 million, attributed to reduced raw materials and consumables for trial production, a decrease in R&D team personnel, and lower third-party contracting costs[39]. - The company has obtained NMPA approval for multiple vascular access devices, including remote access catheters and microcatheters, enhancing its product portfolio for stroke treatment and prevention[25]. - The intracranial aneurysm embolization assist stent received NMPA approval in October 2024 and has commenced sales, indicating successful product commercialization[22]. Corporate Governance - The company has a governance report for the fiscal year ending December 31, 2024, highlighting its commitment to corporate governance practices[95]. - The board consists of three executive directors, three non-executive directors, and three independent non-executive directors, ensuring a balanced distribution of power[107]. - The company has adopted a corporate governance code to enhance management standards and protect shareholder interests[101]. - Independent non-executive directors represent one-third of the board, complying with listing rules regarding independence[110]. - The company has established a nomination policy to evaluate and determine director candidates based on relevant qualifications and experience[116]. Environmental, Social, and Governance (ESG) - The group emphasizes sustainable development by integrating ESG principles into its daily operations and management strategies[182]. - The group has established annual ESG management goals covering resource usage and health safety, with regular reviews to ensure progress[182]. - The company adheres strictly to various environmental laws and regulations, ensuring compliance with national and local environmental protection requirements[196]. - The company emphasizes green development and resource utilization efficiency, aiming for sustainable innovation initiatives[196]. - The company reported total emissions of approximately 34.5 kg of waste gas in 2024, with a density of 12.4 kg per RMB 100 million in revenue, a decrease of about 2% compared to 2023[197]. Management and Workforce - The workforce consisted of 344 full-time employees as of December 31, 2024, with competitive compensation and training programs in place to enhance employee retention[55]. - The company has a strong management team with extensive backgrounds in quality control and regulatory compliance in the medical device industry[63]. - The company is committed to training new employees on corporate culture and compliance with laws and regulations[99]. - The employee gender ratio during the reporting period was 32:68, indicating a commitment to gender diversity within the workforce[136]. Strategic Goals and Market Position - The company aims to enhance brand awareness as a comprehensive provider of neurointerventional devices and expand sales of commercialized products while pushing for the commercialization of in-development products[36]. - The company aims to become a leader in the Chinese neurointerventional medical device market[99]. - The company is exploring opportunities for mergers and acquisitions to strengthen its market position[69]. - The company plans to apply for listing on the Shanghai Stock Exchange's Sci-Tech Innovation Board, reflecting its growth strategy and market ambitions[31].

Core Viewpoint - Shanghai Xinwei Medical Technology Co., Ltd. has achieved a significant milestone in 2024 by reaching a breakeven point, enhancing investor confidence and positioning itself for future profitability [1][2]. Financial Performance - For the year ending December 31, 2024, the company reported revenue of 277.9 million yuan, a year-on-year increase of 19.6%, and a gross profit of 181.7 million yuan, up 11% [2]. - The pre-tax loss narrowed significantly to 12 million yuan, a reduction of 88.3% compared to the previous year, indicating a clear path towards profitability [2]. - The company's cost management efforts led to a decrease in sales and management expense ratio to 49.6%, down 16.6 percentage points year-on-year [2]. Strategic Focus - The company is concentrating on two main strategies: deepening its core business in neurointervention and accelerating overseas market expansion [3]. - In the neurointervention sector, the company has shifted resources towards differentiated therapeutic devices, achieving a 45.5% sales growth in acute ischemic stroke treatment devices and over 100% growth in hemorrhagic stroke treatment devices [3][4]. - The implementation of national centralized procurement policies has facilitated the penetration of the company's products into over 2,500 hospitals, with an active implantation hospital rate exceeding 80% [3]. Overseas Expansion - The company achieved overseas revenue of 8.395 million yuan in 2024, a staggering growth of 684% year-on-year, with Taiwan and India being the primary contributors [4]. - The company has obtained CE or FDA certifications for several key products, enabling entry into international markets, and plans to register products in over 30 countries within the next two years [4][12]. R&D and Innovation - Xinwei Medical is recognized as a leader in the neurointervention medical device sector, with a comprehensive product pipeline covering prevention and treatment of various neurological conditions [6]. - The company has received approvals for 31 medical devices from NMPA, 3 from FDA, and 1 from CE, showcasing its strong R&D capabilities [6]. - Recent product launches include innovative devices that fill gaps in the domestic market, enhancing the company's competitive edge [7]. Market Trends and Future Outlook - The aging population and increasing demand for rehabilitation technologies are expected to drive growth in the neurointervention sector [7]. - The brain-computer interface industry is projected to grow significantly, with a forecasted market size of $1.98 billion in 2023, reaching over $6 billion by 2028 [8]. - The company aims for an annual revenue growth of approximately 35% and a stable profit margin of 15%-20% once sales exceed 500 million yuan [9].

Core Viewpoint - The company reported a significant increase in revenue and a substantial reduction in losses, indicating improved operational efficiency and market positioning in the neuro-interventional medical device sector [1][2]. Financial Performance - The company achieved revenue of RMB 278 million for the fiscal year ending December 31, 2024, representing a year-on-year increase of 19.6% [1]. - Research and development costs amounted to RMB 58.94 million, a decrease of 52.4% compared to the previous year [1]. - The loss attributable to the parent company was RMB 13.62 million, a reduction of 85.51% year-on-year, with a loss per share of RMB 0.36 [1]. - The pre-tax loss narrowed significantly to RMB 12 million, down 88.3% year-on-year, despite a decline in gross margin due to bulk procurement pricing and market competition [1]. Operational Efficiency - The company successfully reduced the expense ratio for sales, distribution, and administrative expenses to 49.6%, down from 66.2% in 2023, reflecting effective cost control and efficiency measures [1]. - The sales volume of acute ischemic stroke treatment devices increased by 45.5%, while revenues from hemorrhagic stroke treatment devices and other interventional devices grew by 104.2% and 109.4%, respectively [1]. Product Development and Market Expansion - The company is focused on upgrading its neuro-interventional business and differentiating its treatment devices to adapt to rapidly changing market conditions [1]. - Research and development efforts are directed towards diverse neuro-interventional treatment devices, with plans to launch at least two major devices in the next 24 months, including self-expanding drug-eluting stents and carotid stents [2]. - The company has received NMPA approval for its intracranial aneurysm embolization assist stent and flow diversion device, which have begun sales [2]. - The company has obtained CE or FDA certifications for several products in overseas markets and is currently conducting over 40 product registrations in 10 countries or regions to expand sales channels [2].

Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6609） 董事會提名委員會工作細則 第一章 總則 第一條 為規範上海心瑋醫療科技股份有限公司（以下簡稱「公司」）董事及高級 管理人員的產生，優化董事會組成，完善公司治理結構，根據《中華人民共和 國公司法》（以下簡稱「《公司法》」）等相關法律、法規、規範性文件、《上海心瑋 醫療科技股份有限公司章程》（以下簡稱「《公司章程》」）和《香港聯合交易所有 限公司證券上市規則》（以下簡稱「《上市規則》」）及中華人民共和國香港特別行 政區其他適用的法律、法規及有關規定，公司特設立董事會提名委員會，並結 合公司實際，制定本《上海心瑋醫療科技股份有限公司董事會提名委員會工作 細則》（以下簡稱「本細則」）。 第二條 董事會提名委員會是董事會按照股東大會決議設立的專門工作機構， 主要職責是擬定公司董事（包括獨立非執行董事）、總經理及其他高級管理人 員的選任程序和標準 ...

執行董事 王國輝先生 （董事長） 張坤女士 韋家威先生 Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6609） 董事名單及其角色與職能 本公司董事會（「董事會」）成員載列如下。 非執行董事 丁魁先生 陳少雄先生 陳剛先生 獨立非執行董事 郭少牧先生 馮向前先生 龔平先生 董事會下轄四個委員會。下表列示董事會委員會的組成： | | 委員會 | 審計委員會 | 薪酬委員會 | 提名委員會 | 戰略委員會 | | --- | --- | --- | --- | --- | --- | | 董事 | | | | | | | 王國輝 | | | M | | C | | 張坤 | | | | M | M | | 韋家威 | | | | | | | 丁魁 | | M | | | M | | 陳少雄 | | | | | | | 陳剛 | | | | | M | | 郭少牧 | | | C | M | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Shanghai HeartCare Medical Technology Corporation Limited （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6609） (I)提名委員會組成變動； (II)僱員代表監事變動； 及 (III)執行董事職責變動 提名委員會組成變動 上海心瑋醫療科技股份有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈， 自2025年3月27日起，王國輝先生不再擔任董事會提名委員會（「提名委員會」） 成員，以加強本公司的企業管治，並履行將於2025年7月1日起實施的香港聯合 交易所有限公司證券上市規則（「上市規則」）有關提名委員會性別多元化的新 規定。張坤女士（「張女士」）已同時獲委任為提名委員會成員。緊隨變動後，提 名委員會將由兩名獨立非執行董事及一名執行董事，即馮向前先生（主席）、郭 少牧先生及張坤女士組成。 ...

Financial Performance - The company reported a revenue of RMB 277.9 million for the fiscal year ending December 31, 2024, representing a year-on-year growth of 19.6%[4] - Gross profit was RMB 181.7 million, with a gross margin of 65.4%, down from 70.5% in the previous year, reflecting a decrease of 5.1 percentage points[3] - The company significantly reduced its pre-tax loss to RMB 12.0 million, an 88.3% improvement compared to a loss of RMB 102.9 million in 2023[4] - The company reported a net loss attributable to equity holders of RMB 13.6 million, significantly reduced from RMB 94.0 million in the previous year, with a basic and diluted loss per share of RMB 0.36 compared to RMB 2.47[6] - Total revenue for 2024 reached RMB 277,899 thousand, an increase of 19.6% compared to RMB 232,344 thousand in 2023[19] - Revenue from medical device sales was RMB 276,931 thousand in 2024, up from RMB 232,344 thousand in 2023, reflecting a growth of 19.2%[19] - Revenue from service provision amounted to RMB 968 thousand in 2024, with no revenue reported in 2023[19] - Revenue from the mainland China market was RMB 269,504 thousand in 2024, compared to RMB 231,273 thousand in 2023, indicating a growth of 16.5%[19] - Other income totaled RMB 17,559 thousand in 2024, down from RMB 22,406 thousand in 2023, representing a decrease of 21.8%[21] - Government subsidies received were RMB 8,793 thousand in 2024, a decrease from RMB 11,211 thousand in 2023, reflecting a decline of 21.5%[21] Cost Management - Research and development costs were RMB 58.9 million, a decrease of 52.4% from RMB 123.8 million in the previous year, indicating effective cost control[3] - Sales and distribution expenses decreased by 10.4% to RMB 137.8 million, contributing to a lower expense ratio of 49.6% compared to 66.2% in 2023[4] - Administrative expenses decreased from RMB 74.6 million for the year ended December 31, 2023, to RMB 58.2 million for the year ending December 31, 2024, primarily due to a reduction in professional service fees[62] - Financial costs decreased from RMB 2.2 million for the year ended December 31, 2023, to RMB 1.7 million for the year ending December 31, 2024[65] Product Development and Market Strategy - The company achieved a 45.5% increase in sales of acute ischemic stroke treatment devices, with hemorrhagic stroke treatment devices and other interventional devices growing by 104.2% and 109.4%, respectively[4] - The company plans to launch at least two major neurointerventional devices in the next 24 months to address the growing demand for stroke treatment in the aging Chinese market[5] - The company has obtained CE or FDA certifications for several products and is currently registering over 40 products in 10 countries, laying the groundwork for long-term overseas sales goals[5] - The company aims to enhance its brand recognition as a comprehensive provider of neurointerventional devices and accelerate the commercialization of its pipeline products[53] - The company is focused on developing innovative medical devices in high-growth potential markets to create a competitive product portfolio beyond its neurointerventional business[53] Financial Stability - Total assets decreased to RMB 1,106.3 million in 2024 from RMB 1,141.5 million in 2023, while total liabilities also decreased, indicating improved financial stability[8] - The total trade receivables increased to RMB 97,381,000 in 2024 from RMB 78,659,000 in 2023, with an expected credit loss of RMB 2,668,000, representing a credit loss rate of 2.74%[28][31] - The company recognized a cumulative tax loss of RMB 686,522,000 as of December 31, 2024, which can be utilized to offset future taxable profits over the next 2 to 10 years[25] - The company has been granted a preferential income tax rate of 15% as a high-tech enterprise, applicable for the years ending December 31, 2023, and December 31, 2024[24] - The company has no supplier financing arrangements, thus recent accounting standard revisions will not impact its financial statements[14] - The company expects no significant impact on its financial performance or position from newly issued accounting standards in the foreseeable future[16] Corporate Governance - The company has adopted the corporate governance code to enhance management standards and protect shareholder interests[84] - The audit committee consists of three members, including two independent non-executive directors, ensuring compliance with listing rules[86] - The company confirms that all directors and supervisors have adhered to the standard code during the reporting period[85] - The company’s consolidated financial statements for the reporting period have been audited and comply with relevant accounting standards[87] - The chairman and CEO roles are held by the same individual, which deviates from the corporate governance code, but the board believes it enhances leadership effectiveness[84] Shareholder Returns - The company did not declare or pay any dividends during the year, consistent with the previous year[26] - The board does not recommend the payment of a final dividend for the reporting period, consistent with the previous year[81] Future Outlook - The company plans to apply for A-share listing on the Shanghai Stock Exchange's Sci-Tech Innovation Board[54] - The company plans to hold its annual general meeting on May 26, 2025[89] - The company’s shares are listed on the Hong Kong Stock Exchange under the stock code 6609[89]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 董事會召開日期 上海心瑋醫療科技股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此 宣佈，本公司將於2025年3月27日（星期四）舉行董事會會議，藉以（其中包括） 審議及批准本公司及其附屬公司截至2024年12月31日止年度之全年業績及其發 佈，以及考慮建議派付末期股息（如有）。 承董事會命 上海心瑋醫療科技股份有限公司 Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6609） 董事長 王國輝 上海，2025年3月17日 於本公告日期，執行董事為王國輝先生、張坤女士及韋家威先生；非執行董事為丁魁先生、 陳少雄先生及陳剛先生；及獨立非執行董事為郭少牧先生、馮向前先生及龔平先生 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6609） 根據上市規則第13.51B(2)條及第13.51(2)條作出的公告 王國輝 上海，2025年3月6日 於本公告日期，執行董事為王國輝先生、張坤女士及韋家威先生；非執行董事為丁魁先生、 陳少雄先生及陳剛先生；及獨立非執行董事為郭少牧先生、馮向前先生及龔平先生。 茲提述聯交所於2025年3月6日發佈的監管公告（「監管公告」），內容有關針對花 樣年、彩生活服務集團有限公司（聯交所上市公司，股份代號：1778）以及兩間 公司的若干董事或前任董事（包括郭先生）的公開譴責。根據監管公告，聯交所 發現（其中包括），(i)花樣年違反上市規則第十 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Shanghai HeartCare Medical Technology Corporation Limited 臨時股東大會及該等類別股東大會的出席情況 董事會欣然宣佈，本公司於2024年11月7日（星期四）上午十時正假座中國上海 市自由貿易試驗區臨港新片區正博路356號38幢2層心瑋廳先召開臨時股東大會， 並於臨時股東大會結束後隨即召開該等類別股東大會。 臨時股東大會及該等類別股東大會由董事會根據中華人民共和國公司法及組 織章程細則召開，由執行董事兼董事會主席王國輝先生主持。本公司全體董事 王國輝先生、張坤女士、韋家威先生、丁魁先生、陳少雄先生、陳剛先生、郭 少牧先生、馮向前先生及龔平先生均親身或以電子方式出席臨時股東大會及 該等類別股東大會。 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6 ...